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Abstract 
 
Background: There is a strong association between chromosomal abnormalities and laboratory features and 
clinical course of the B-cell chronic lymphocytic leukemia (B-CLL). The aim of this study was to investigate the 
frequency and correlation of cytogenetic aberrations with laboratory and clinical features of the disease. 
 
Methods: Clinical and laboratory features of 65 CLL patients were collected from their hospital profiles and their 
blood and/or bone marrow were examined by conventional cytogenetics and interphase FISH methods.  
 
Results: Conventional cytogenetic methods identified 27.7% chromosomal abnormalities in 65 patients. I-FISH 
analysis for del13q, del11q and trisomy 12 revealed abnormality in 75.4% of patients. The results showed that I-
FISH improved the detection rate of chromosomal abnormalities and it enhanced detection. Statistical analysis 
was performed on sex, age, family history, Rai stage and CD markers on trisomy 12, del 11q and del 13q sub-
groups. There was a high frequency of Ray stages I and II within del13q subgroup, Rai stages III and IV within 
del11q subgroup and Rai stage II within trisomy 12 subgroup. Mean of CD38 in patients with del 11q was signifi-
cantly higher than mean of patients with trisomy 12 and del 13q. 
 
Conclusion: High level of CD38 and presence of del11q indicated a poor prognosis and low level of CD38 and 
presence of del13q was indicative of good prognosis in Iranian B-CLL patients. Trisomy 12 had an intermediate 
prognostic value. 
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Introduction 
 
B-cell Chronic Lymphocytic Leukemia (B-CLL) is 
the most frequent leukemia in Western countries and 
has an annual incidence of 20 new cases per 100,000 
inhabitants above age of 60 years and comprises 30% 
of all leukemia patients. The gender ratio varies from 
1.5 to 2.1 males to 1 female.1 It is still a common 
cancer in Iran.2 B-CLL is characterized by the relent-
less accumulation of monoclonal B-cell with the ap-
pearance of small mature lymphocytes and with char-
acteristic immunophenotype (CD5, CD19, CD20, and 
CD23 positive).3 
Clinical course of the disease is highly variable. 
Some patients have stable disease with normal surviv-
ing without requiring any specific therapy, while others 
develop a progressive form of the disease despite ag-
gressive treatments.4 Transplantation of hematopoietic 
stem cells (HSCT) has become the standard treatment 
for many patients with Chronic Lymphocytic Leuke-
mia.5 Patients are asymptomatic at presentation but 
with progression of the disease, they develop fatigue, 
autoimmune hemolytic anemia, infection, 
splenomegaly and lymphadenopathy.2,6 Because of 
the variable phenotype of the disease, several research 
groups have tried to identify prognostic factors to 
predict the clinical outcome of the disease.7 Age, sex, 
clinical staging (Rai or Binet staging), blood lympho-
cyte count, lymphocyte doubling time, morphological 
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cell features, immunophenotype and genetic markers 
have all been identified as important prognostic fac-
tors.8 Chromosomal abnormalities are the genetic 
markers that play an important role in diagnosis and 
prediction of B-CLL. Deletion in 13q14, 11q22, 
17p13 and trisomy 12 are the most common chromo-
somal abnormalities that have been observed in B-
CLL. Deletion in 11q22 and 17p13 are associated with 
poor prognosis and deletion of 13q14 was demon-
strated to have a good prognosis.9 Trisomy 12 is con-
sidered to confer a worse prognosis.10 Conventional 
cytogenetics and interphase FISH analysis routinely 
are used to define chromosomal abnormalities in B-
CLL. Conventional cytogenetics can detect 40-50 % of 
abnormalities. The use of cytogenetic analysis has 
been often hampered by low in vitro mitotic rate of 
leukemic B-cells and the poor response to mitogens.11 
Interphase FISH is more powerful and sensitive, and it 
can detect 80% of chromosomal abnormalities.12 
The aims of this study were first to investigate the 
incidence of chromosomal abnormalities in B-CLL 
patients undergoing conventional cytogenetic meth-
ods and FISH technique and second to evaluate the 
correlation between these abnormalities and prognos-
tic factors such as age, sex, blood lymphocyte count, 
family history, Rai staging and CD markers.  
 
 
Materials and Methods  
 
Patients were recruited during 20 months between 
2006 and 2008 from four major hematol-
ogy/oncology hospitals in Tehran, Capital of Iran. 
The patients were either new subjects or they were 
already identified as B-CLL cases and were not tak-
ing any therapeutic treatment six months prior to 
sampling. Their diagnostic inclusion criteria were 
based on the National Cancer Institute Working 
Group (NCI-WG) guidelines for diagnosis of B-
CLL.13 Seventy patients were enrolled. Immunophe-
notypic data and blood parameters were collected 
from patient's hospital files; and questions on age, 
family history, onset of disease and treatment meas-
ures were also provided. Patients having more than 
either one first degree relative or two second degree 
relatives affected by any type of cancer in their fam-
ily were considered as positive family history.  
Blood samples and /or bone marrow aspiration 
were taken in heparinazed collection tubes and were 
transferred immediately to laboratory for experimen-
tal work. The study was approved in the Ethical 
Committee of the School of Medical Sciences of Tar-
biat Modares University. Each patient was also in-
formed of the enrollment procedure for taking part in 
the study and signed the written consent. 
Peripheral blood and bone marrow samples were 
differently pretreated for culturing. Bone marrow from 
22 and peripheral blood from 36 patients were pro-
vided. Both specimens were also collected from 7 pa-
tients. Peripheral blood was first washed with minimal 
culture medium (RPMI-1960 with no further supple-
mentation) three times and then white blood cells 
(WBC) were counted by Neubauer hemocytometer. 
Bone marrow specimens only were counted by 
Neubauer hemocytometer. 106cells/ml was cultured in 
5 ml completed culture medium [RPMI-1960 medium 
(Gibco, USA), 10% fetal bovine serum (Gibco, USA), 
1% antibiotics and 1% L-glutamine (Gibco,USA)]. 
Five cultures were set up for each patient whose condi-
tions were as follows: overnight (ONC), 24 hours and 
72 hours without mitogen stimulation and 24 hours and 
72 hours with phorbol myristate acetate (50 ng/mL) 
(Biomol, Germany). Harvesting and slide preparation 
took place according to standard cytogenetic methods 
(Hypotonic treatment, and methanol-acetic acid (Merk, 
Germany; 3:1 ratio of fixation). G-banding technique 
was used. Up to 20 metaphases were analyzed for each 
patient utilizing Applied Imaging Powergene Intelligent 
Karyotyping software (Applied Imaging, USA) accord-
ing to International System for Human Cytogenetic 
Nomenclature.14 
The FISH analysis was performed on slides taken 
from the 24-hours culture without stimulation. Dual-
color probes were used to evaluate del 13q14 and del 
11q22 (Cytocell, UK) but trisomy 12 was analyzed by 
centromeric probe purchased from Kreatech Diagnos-
tics (Netherlands). FISH assay was conducted accord-
ing to the manufacture's instructions. For each probe 
per patient, two hundred nuclei were analyzed by Zeiss 
Axioplan 25 position fluorescence microscope (Zeiss, 
Germany). PowerGene software (MacProbe Version 
4.3, USA) was used to capture images. The cut off 
point for positive values (i.e. Mean of normal control 
+3 standard deviations) established in bone marrow 
and peripheral blood from 6 controls with CML, were 
8.7 for del 13q14, 7.71 for del 11q22  and 7.2 for 
trisomy 12 probes.  
SPSS software program (SPSS for Windows, ver-
sion 15, Chicago, IL, USA) was used for statistical 
analysis. Correlations between Rai staging and CD 
markers were measured by means of Spearman correla-
tion coefficient. Comparison of numerical variables 
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such as CD markers, WBC and lymphocyte count be-
tween three cytogenetic subgroups were performed us-
ing ANOVA test. Other variables such as Rai staging 
and family history between cytogenetic subgroups were 
analyzed using Chi Square, Kruskall Wallis and Fisher ̓̓̓s 
Exact tests respectively. The association of untreated 
and post-treatment categories with chromosomal ab-
normalities was analyzed using Fisher ̓̓̓s Exact test. A p 
value less than 0.05 was considered significant. 
 
 
Results 
 
The culture of five cases failed and 65 specimens 
were successfully analyzed. Patients' clinical charac-
teristics were summarized in Table 1. Forty six cases 
were male and 19 were female. Gender ratio was 2.8 
males to 1 female. Patients were between 42 to 81 
years old. The mean age of the patients was 62.3±1.3 
years old. They could be classified into three sub-
groups. Twenty four patients presented with B-CLL 
diagnosis in the course of this study (new cases). Fol-
lowing the medical diagnosis, they were recruited to 
this study and were subjected to clinical and labora-
tory examination. Forty one cases suffered from the 
disease from 13 to 300 months. Nevertheless, patients 
of this category could be further subdivided into two 
groups in terms of clinical outcome: 27 patients re-
quiring treatment (including chemotherapy) and 14 
having no need to treatment. The first group was des-
ignated as post-treatment patients and was off treat-
ment in the six months prior to entry to this study, 
whereas the second group did not require stringent 
treatment and just a routine blood test as check up 
was carried out.  
Analysis of bone marrow and peripheral blood of 
seven patients showed the same results, i.e. similar 
abnormalities were observed by karyotyping and 
FISH methods. Number of the bone marrow speci-
mens in Table 1 is actually the sum of cases with 
bone marrow and those who provided both bone mar-
row and peripheral blood. Distribution of Rai staging 
and family history is also available in Table 1. 
Conventional cytogenetic methods revealed chro-
mosomal abnormalities in 18 cases (27.7%). Deletion 
13q (five cases), deletion 11q (four cases) and 
trisomy 12 (five cases) were the most common ab-
normalities in all cases. Monosomy 21 and 
monosomy 17 were also identified in three and one 
patients respectively. Complex abnormalities were 
observed in 12 cases but, only in one metaphase in 
each case, however they were not included.  
Interphase FISH for del 13q was performed on 53 
patients; out of which 21 cases ( 21/53 or 40%) dem-
onstrated the microdeletion; and 64 patients were ana-
lyzed  for del 11q; out of which 13 cases (13/64 or 
20.3%) turned out to have the microdeletion. Among 
all cases analyzed by FISH method for trisomy 12, 
fifteen cases (15/62 or 24%) revealed chromosomal 
abnormalities. In total, about 75.4% of all cases 
(49/65) showed the abnormalities by FISH technique. 
Clinical characteristics of these three subgroups and 
undetected group have been provided in Table 1. 
The range of abnormalities was between 23% and 
60% in different patient's specimens. In comparison 
to cut off values, this range verified the abnormalities 
in the patients properly.  
Fourteen patients who were detected by conven-
tional cytogenetic techniques as trisomy 12, del 11q 
and del 13q were confirmed by FISH method. The 
patients with monosomy 21 and 17 (4 cases of 65 pa-
tients or 6.1%) were just identified by conventional 
cytogenetic methods. Therefore FISH and conven-
tional cytogenetic methods together identified 81.5% 
Table 1: Clinical and laboratory characteristics of Iranian B-CLL patients 
Fam. His. Rai stage Tissue Age Sex No. Patient 
Neg Pos IV III II I O PB BM     F M   
        <50  50-60  60-70   >70    
44 21 5 14 28 11 7 36 29 14 23 17 11 19 46 65 All 
16   5 0   0 12   5 4 10 11   5   8   5   3   6 15 21 Del 13q 
  8   5 3   6   2   2 0   9   4   1   4   5   3   4   9 13 Del 11q 
10   5 1   4   8   1 1   9   6   4   5   3   3   4 11 15 Trisomy 12 
10   6 1   4   6   3 2 10   6   4   6   4   2   5 11 16 Undetected 
Abbreviations: No., number; Fam. His., family history; M, male; F, female; <50, less than 50 years; 50-60, be-
tween 50 and 60 years; 60-70, between 60 and 70 years; >70, more than 70 years; BM, bone marrow; PB, pe-
ripheral blood; Pos, positive; Neg, negative 
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(53/65) of patients as having chromosomal abnor-
malities. A brief overview of cytogenetics and FISH 
results were illustrated in Figure 1. 
Correlation of Rai staging with CD38 was signifi-
cant (p=0.05), but it was not significant with CD5, 
CD19, CD20, CD23, WBC, PLT, age and family his-
tory. Secondly we selected patients with trisomy12, 
13q and 11q deletion and analyzed those three sub-
groups with other variables. Rai staging in three sub-
groups had a significant distribution (Chi square 11.4 
at p=0.01 level). Trisomy 12 was mostly distributed 
in Rai stage II, del 13q was mainly seen in low level 
Rai stages (I and II), and 11q deletion patients tended 
to cluster with high level of Rai stages (III and IV). 
As far as the association between family history and 
three subgroups was concerned, analysis by Fisher's 
Exact test did not show any significance (p=0.302 for 
1-side and p=0.417 for 2-side Exact significance). 
Age, CD5, CD19, CD20, CD23, did not have signifi-
cance at the 0.05 in the two subgroups; just CD38 
was significant (p=0.002). It means that patients with 
del 11q, trisomy 12 and del 13q had high, moderate 
and low value of CD38 respectively. 
Fisher's Exact test was significant (p=0.026 for 1-
side and p=0.031 for 2-side Exact significance). It 
showed that post treatment subgroup correlated with 
trisomy 12 and del 11q abnormalities, whereas  
untreated subgroup correlated with del 13q. 
FISH analysis revealed 75.4% chromosomal ab-
normality in total, comprising 40% for del 13q, 
20.3% for del 11q and 24% for trisomy 12. The re-
sults of present study and the other published studies 
have been summarized in Table 2. 
 
 
Discussion  
 
Although CLL is the most prevalent type of leukemia, 
its annual incidence of new cases is low and as a re-
sult the number of new cases is generally low.2 So the 
number of new cases comprised slightly over a third 
of the present study. However some female patients 
refrained from taking part in the study, as a result, the 
gender ratio shifted towards more males. There were 
two reasons why bone marrow specimen was less 
than peripheral blood samples. First, a great number 
of recruited patients were those who had already been 
diagnosed as B-CLL and the physicians did not feel 
necessary to perform another bone marrow aspiration, 
so patients with bone marrow specimen reduced. 
Second, following careful analysis of seven patients 
from whom, we had both bone marrow and peripheral 
blood specimens, which demonstrated no differences 
in cytogenetic outcome between the two tissues,  
 
Fig. 1: Bar chart of detection rate of conventional cytogenetic methods, FISH technique and total rate. 
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patients refusing bone marrow aspiration were en-
rolled in the study and this increased the number of 
peripheral blood specimens.  
The weak mitogen stimulation of malignant cells 
in B-CLL and the fact that unlike other forms of leu-
kemia, their cells are in G0 phase of cell cycle led to a 
decrease of metaphase in cytogenetic analysis. More-
over most of their chromosomes were short and small 
and less liable to good banding. These factors made it 
very difficult to identify structural abnormalities such 
as translocation, inversion and microdeletion. Almost 
exclusively numerical gain or loss and very big dele-
tions are recognizable. For these reasons, we could 
just identify 27.7% of chromosomal abnormalities by 
conventional cytogenetic methods.  
FISH analysis revealed 75.4% chromosomal ab-
normality in total, comprising 40% for del 13q, 
20.3% for del 11q and 24% for trisomy 12. The re-
sults of present study and the other published studies 
have been summarized in Table 2. As it is evident, 
each of these chromosomal abnormalities have a wide 
range between different population: 32%-69% for del 
13q, 5.1%-23% for del 11q and 11%-25% for trisomy 
12. Nevertheless, in all studied groups the order of 
abnormality with regard to prevalence is similar: the 
most common being del 13q, followed by trisomy 12 
and del 11q. As far as detection rate for FISH analysis 
was concerned, variation between the studied groups 
also existed, and our study result was within this 
range: 50.6%-82%. Comparison of these data indi-
cated clearly that these findings are similar. It could 
be concluded that the type and the rate of chromosomal 
aberrations in Iranian B-CLL patients were similar to 
other countries and the underlying genetic mechanisms 
leading to the disease could not be different. However, 
identification of such a higher frequency of abnormali-
ties by FISH technique compared to conventional cy-
togenetic methods illustrated greater sensevity of FISH 
analysis as against conventional karyotyping method. 
Therefore, FISH testing helps outstandingly in estab-
lishing diagnosis for these patients. 
As far as the correlation between immunophenotyp-
ing and cytogenetic results is concerned, we identified 
that amongst the CD markers only CD38 showed sig-
nificant correlation with Rai staging. The coefficient of 
correlation of 0.3 between these two variables showed 
an intermediate relationship. This means that along 
with the increase in Rai staging, the CD38 also in-
creases. This finding in its own right confirms the role 
of CD38 as a prognostic factor. Statistical analysis of 
distribution of Rai stages within the three cytogenetic 
subgroups of patients illustrated that stages III and IV 
on the one hand and I and II on the other hand had sig-
nificant correlation with del 11q and del 13q respec-
tively Considering the fact that stages III and IV are 
correlated with worsening of the patient's condition, it 
could be concluded that del 11q indicate poor progno-
sis and on the other hand del 13q indicates good prog-
nosis. However, occurrence of trisomy 12 in Rai stage 
II and weak correlation with CD38 suggested an in-
termediate prognostic value for this abnormality. Sig-
nificance of the relation between the mean of CD38 in 
Table 2: Detection rates of three cytogenetic subgroups analyzed by FISH in different studies 
No. FISH Ab. (%) Trisomy 12 (%) Del 11q (%) Del 13q (%) Country Reference 
  54 - 18.5   5.5 - Israel1 Amiel et al.  
100 64 11 23 40 USA5 Glassman et al.  
  91 72 21   7 46 USA9 Aoun et al. 
  16 63 19 14 69 Korea10 Chang et al. 
217 70 16 12 54 Czech14 Sindelarova et al. 
 13   65 68.4 19.2 17.5 42.1 Spain15 Ripolles et al. 
  57 80.7 21.9 - 63.2 Argentina16 Chena et al.  
113 77 25 15 64 USA17 Dewald et al.  
180 62 23   9 35 Spain18 Quijano et al.  
325 82 16 18 55 Germany19 Dohner et al.  
  79 50.6 15.2   5.1 32.9 Turkey20 Dorak et al.  
  65 75.4 24 20.3 40 Iran Present study 
Abbreviations: Ab., Abnormality; No., number of cases. 
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del 11q patients compared to CD38 magnitude in del 
13q patients once again reiterated the importance of 
CD38 evaluation for the prognosis of the patients. 
Comparison of untreated and post-treatment pa-
tients indicated that aberrations of del 11q and triso-
my 12 were seen more frequently in those requiring 
treatment, whereas del 13q was seen more in the un-
treated subgroup. As stringent treatment such as che-
motherapy is carried out in advanced and progressive 
form of the disease, it could be concluded that del 11q 
and trisomy 12 aberrations were associated with pro-
gressive form and conversely, del 13q correlated with 
stable and indolent form of the disease. 
Cytogenetic and immunophenotypic results were 
similar in familial and sporadic B-CLL patients. 
Some other studies that examined familial B-CLL 
cases have also suggested similar finding.15,16 
In conclusion, utilization of I-FISH technique en-
hanced diagnosis rate in B-CLL patients and also 
higher amount of CD38 and or presence of del 11q 
indicated poor prognosis whereas lower amount of 
CD38 and presence of del 13q pointed at good prog-
nosis. Trisomy 12 had an intermediate prognostic 
value in our B-CLL patients. 
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